BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 22314389)

  • 1. Metastatic pheochromocytoma and paraganglioma: focus on therapeutics.
    Plouin PF; Fitzgerald P; Rich T; Ayala-Ramirez M; Perrier ND; Baudin E; Jimenez C
    Horm Metab Res; 2012 May; 44(5):390-9. PubMed ID: 22314389
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The diagnosis and management of malignant phaeochromocytoma and paraganglioma.
    Chrisoulidou A; Kaltsas G; Ilias I; Grossman AB
    Endocr Relat Cancer; 2007 Sep; 14(3):569-85. PubMed ID: 17914089
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Malignant pheochromocytomas and paragangliomas: molecular signaling pathways and emerging therapies.
    Santarpia L; Habra MA; Jiménez C
    Horm Metab Res; 2009 Sep; 41(9):680-6. PubMed ID: 19343618
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-dose 131I-metaiodobenzylguanidine therapy for 12 patients with malignant pheochromocytoma.
    Rose B; Matthay KK; Price D; Huberty J; Klencke B; Norton JA; Fitzgerald PA
    Cancer; 2003 Jul; 98(2):239-48. PubMed ID: 12872341
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Malignant pheochromocytomas and paragangliomas - the importance of a multidisciplinary approach.
    Andersen KF; Altaf R; Krarup-Hansen A; Kromann-Andersen B; Horn T; Christensen NJ; Hendel HW
    Cancer Treat Rev; 2011 Apr; 37(2):111-9. PubMed ID: 20675056
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Malignant pheochromocytomas and paragangliomas: a phase II study of therapy with high-dose 131I-metaiodobenzylguanidine (131I-MIBG).
    Fitzgerald PA; Goldsby RE; Huberty JP; Price DC; Hawkins RA; Veatch JJ; Dela Cruz F; Jahan TM; Linker CA; Damon L; Matthay KK
    Ann N Y Acad Sci; 2006 Aug; 1073():465-90. PubMed ID: 17102115
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 131I-metaiodobenzylguanidine and peptide receptor radionuclide therapy in pheochromocytoma and paraganglioma.
    Jungels C; Karfis I
    Curr Opin Oncol; 2021 Jan; 33(1):33-39. PubMed ID: 33093336
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Management and treatment of pheochromocytomas and paragangliomas.
    Mannelli M
    Ann N Y Acad Sci; 2006 Aug; 1073():405-16. PubMed ID: 17102109
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 131I-MIBG therapy of neural crest tumours (review).
    Troncone L; Rufini V
    Anticancer Res; 1997; 17(3B):1823-31. PubMed ID: 9179240
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nuclear medicine therapy of pheochromocytoma and paraganglioma.
    Troncone L; Rufini V
    Q J Nucl Med; 1999 Dec; 43(4):344-55. PubMed ID: 10731785
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metastatic pheochromocytoma and paraganglioma: Management of endocrine manifestations, surgery and ablative procedures, and systemic therapies.
    Jasim S; Jimenez C
    Best Pract Res Clin Endocrinol Metab; 2020 Mar; 34(2):101354. PubMed ID: 31685417
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Update on the management of unusual neuroendocrine tumors: pheochromocytoma and paraganglioma, medullary thyroid cancer and adrenocortical carcinoma.
    Strosberg JR
    Semin Oncol; 2013 Feb; 40(1):120-33. PubMed ID: 23391119
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hereditary pheochromocytoma and paraganglioma.
    Mazzaglia PJ
    J Surg Oncol; 2012 Oct; 106(5):580-5. PubMed ID: 22648936
    [TBL] [Abstract][Full Text] [Related]  

  • 14. I-131 Metaiodobenzylguanidine Therapy of Pheochromocytoma and Paraganglioma.
    Carrasquillo JA; Pandit-Taskar N; Chen CC
    Semin Nucl Med; 2016 May; 46(3):203-14. PubMed ID: 27067501
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment for Malignant Pheochromocytomas and Paragangliomas: 5 Years of Progress.
    Jimenez P; Tatsui C; Jessop A; Thosani S; Jimenez C
    Curr Oncol Rep; 2017 Oct; 19(12):83. PubMed ID: 29081018
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pheochromocytoma and paraganglioma in children: a review of medical and surgical management at a tertiary care center.
    Pham TH; Moir C; Thompson GB; Zarroug AE; Hamner CE; Farley D; van Heerden J; Lteif AN; Young WF
    Pediatrics; 2006 Sep; 118(3):1109-17. PubMed ID: 16951005
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Peptide Receptor Radionuclide Therapy as a Novel Treatment for Metastatic and Invasive Phaeochromocytoma and Paraganglioma.
    Mak IYF; Hayes AR; Khoo B; Grossman A
    Neuroendocrinology; 2019; 109(4):287-298. PubMed ID: 30856620
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Malignant pheochromocytoma and paraganglioma: management options.
    Corssmit EPM; Snel M; Kapiteijn E
    Curr Opin Oncol; 2020 Jan; 32(1):20-26. PubMed ID: 31599769
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metastatic pheochromocytoma and paraganglioma: recent advances in prognosis and management.
    Hamidi O
    Curr Opin Endocrinol Diabetes Obes; 2019 Jun; 26(3):146-154. PubMed ID: 30893083
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An update on adult forms of hereditary pheochromocytomas and paragangliomas.
    Dariane C; Goncalves J; Timsit MO; Favier J
    Curr Opin Oncol; 2021 Jan; 33(1):23-32. PubMed ID: 33186184
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.